1. Home
  2. INTA vs IRON Comparison

INTA vs IRON Comparison

Compare INTA & IRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Intapp Inc.

INTA

Intapp Inc.

HOLD

Current Price

$42.22

Market Cap

3.1B

Sector

Technology

ML Signal

HOLD

Logo Disc Medicine Inc.

IRON

Disc Medicine Inc.

HOLD

Current Price

$78.67

Market Cap

3.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
INTA
IRON
Founded
2000
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.1B
3.1B
IPO Year
2021
2020

Fundamental Metrics

Financial Performance
Metric
INTA
IRON
Price
$42.22
$78.67
Analyst Decision
Buy
Strong Buy
Analyst Count
7
11
Target Price
$41.43
$103.18
AVG Volume (30 Days)
715.0K
354.8K
Earning Date
05-05-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$577,805,000.00
N/A
Revenue This Year
$15.91
N/A
Revenue Next Year
$13.78
$283.52
P/E Ratio
N/A
N/A
Revenue Growth
14.62
N/A
52 Week Low
$19.01
$40.00
52 Week High
$47.93
$99.50

Technical Indicators

Market Signals
Indicator
INTA
IRON
Relative Strength Index (RSI) 67.06 48.57
Support Level $42.11 $70.73
Resistance Level $45.70 $82.74
Average True Range (ATR) 1.61 2.75
MACD -0.12 -0.35
Stochastic Oscillator 65.03 44.49

Price Performance

Historical Comparison
INTA
IRON

About INTA Intapp Inc.

Intapp Inc is a provider of industry-specific, cloud-based software solutions for the professional and financial services industry. It empowers private capital, legal, accounting, and consulting firms with the technology needed to meet rapidly changing client, investor, and regulatory requirements. Geographically, it derives a majority of its revenue from the United States and also has a presence in the United Kingdom and the Rest of the world.

About IRON Disc Medicine Inc.

Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs), including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.

Share on Social Networks: